We are very pleased to announce that the trial on the role of HE4 in the follow-up of advanced ovarian, Fallopian tube and primary peritoneal cancer has been opened for the enrollment. Since the calculated size of the group is relatively small (150), we are conviced the enrollment will be complete within a relatively short time. We consider this trial to be a great opportunity for CEEGOG and some other centers.

The Principal investigators are Jiri Presl (UH Pilsen, CZ) and Vit Weinberger (UH Brno, CZ).

We are looking forward to cooperating with you and we really appreciate your support for this trial. For more information, please do not hesitate to contact CEEGOG office.